Trial reportClinical obesity2021
Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial.
Trial report in Clinical obesity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.Obesity (Silver Spring, Md.) · 2025Pooled it
- The Effect of Exercise for the Prevention of Bone Mass After Bariatric Surgery: a Systematic Review and Meta-analysis.Obesity surgery · 2022Pooled it
- Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo-controlled study.Obesity (Silver Spring, Md.) · 2025Trial
- Why Do We Lose Bone During Weight Loss: Can It Be Prevented?Current osteoporosis reports · 2026Review
- The impact of lifestyle-based weight loss in older adults with obesity on muscle and bone health: a balancing act.Obesity (Silver Spring, Md.) · 2025Review
- Nutrition and Aging Biology: Summary of a Research Centers Collaborative Network Workshop and Research Needs.Current developments in nutrition · 2025Article
- Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity.Current osteoporosis reports · 2025Review
- Obesity and Skeletal Fragility.The Journal of clinical endocrinology and metabolism · 2024Review
- Strategies to reduce the onset of sleeve gastrectomy associated bone loss (STRONG BONES): Trial design and methods.Contemporary clinical trials communications · 2023Article
- Protocol for a pilot randomised controlled trial of zoledronic acid to prevent bone loss following sleeve gastrectomy surgery.BMJ open · 2021Article
- Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: Results from a pilot randomized controlled trial.JCSM rapid communicationsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The purpose of this study was to explore the efficacy of 150 mg once monthly oral risedronate use in the prevention of sleeve gastrectomy (SG) associated bone loss. Twenty-four SG patients (56 ± 7 years, 83% female, 21% black) were randomized to risedronate or placebo for 6 months, with an optional 12-month assessment. Outcome measures included 6 (n = 21) and 12 (n = 14) month change in dual energy x-ray absorptiometry-acquired regional areal bone mineral density (aBMD). Six-month treatment effect estimates [mean (95% CI)] revealed significant between group aBMD differences at the femoral neck [risedronate: +0.013 g/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.